Navigation Links
Ikaria® Completes Patient Enrollment in Pivotal Phase III Trial for Bronchopulmonary Dysplasia
Date:2/27/2012

HAMPTON, N.J., Feb. 27, 2012 /PRNewswire/ -- Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, today announced that it has enrolled the last patient into its Pivotal Phase III trial investigating the use of inhaled nitric oxide (iNO) in premature infants with bronchopulmonary dysplasia (BPD).  The trial, which commenced in December 2009, enrolled its last patient six weeks ahead of schedule. The trial design includes a one-year follow-up assessment, as discussed with the U.S. Food and Drug Administration (FDA).

Bronchopulmonary dysplasia is a cause of chronic lung disease that develops most commonly in pre-term infants (less than 30 weeks of gestational age) with birth weights less than 1,250 grams who are treated with oxygen and positive-pressure ventilation. Bronchopulmonary dysplasia is even more pronounced in very pre-term infants (less than 26 weeks of gestational age) with birth weights less than 1,000 grams and who have been treated for respiratory distress syndrome.

This multi-center, double blind, placebo-controlled, randomized clinical trial, entitled, Inhaled Nitric Oxide for the Prevention of Bronchopulmonary Dysplasia in Preterm Infants, or the "NewNO Trial," aims to determine whether preterm infants who require mechanical ventilation or positive pressure support at any point during days 5 to 14 after birth may benefit from treatment with iNO. In eligible subjects, iNO was administered continuously at a starting dose of 20ppm for a duration of 24 days.

"The treatment of BPD is an area of great interest and much debate within the neonatology community given the challenges in treating this condition," stated Daniel Tasse, Chairman and CEO of Ikaria.  "We are hopeful that the data from this trial will provide the definitive answers the medical community has been seeking, particularly in light of the recommendations generated by the 2010 NIH Consensus Conference on BPD."

"Enthusiastic enrollment, which allowed us to beat the original enrollment timeline, speaks both to the unmet medical need and the profound interest by the medical community to address BPD," added Douglas A. Greene, M.D., Executive Vice President of Research & Development at Ikaria.

Inhaled nitric oxide selectively relaxes the cells of the pulmonary vasculature, resulting in increased blood flow through the lungs and delivery of more oxygenated blood to the body. Inhaled nitric oxide may also have beneficial effects on the development of pulmonary blood vessels and airspaces.  

Inhaled nitric oxide is available as INOMAX® (nitric oxide) for inhalation, a vasodilator, which, in conjunction with ventilation and other appropriate agents, treats term and near-term newborns (>34 weeks gestation) with hypoxic respiratory failure associated with evidence of pulmonary hypertension.  INOMAX is not approved for use in BPD.

About INOMAX®
INOMAX® is a vasodilator, which, in conjunction with ventilator support and other appropriate agents, is indicated for the treatment of term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.

INOMAX should not be used in the treatment of neonates known to be dependent on right-to-left shunting of blood. Abrupt discontinuation of INOMAX may lead to a worsening condition. Methemoglobinemia is a dose-dependent side effect of inhaled nitric oxide therapy.  Nitrogen dioxide (NO2) forms rapidly in gas mixtures containing nitric oxide and oxygen, and therefore may cause airway inflammation and damage. Methemoglobin, NO2, and FiO2 should be monitored during nitric oxide administration. 

Please see attached prescribing information.  For additional information about INOMAX, please visit www.inomax.com

About Ikaria, Inc.
Ikaria, Inc. is a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients. The company's lead product is INOMAX® (nitric oxide) for inhalation, the only FDA-approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants. It is offered through the INOMAX therapy package, an all-inclusive offering of drug product, drug-delivery system, on-site training and 24/7/365 technical assistance and support. The INOMAX therapy package also is marketed in Puerto Rico, Canada, Australia, Mexico and Japan. The company is investigating additional indications for INOMAX in bronchopulmonary dysplasia, and for inhaled nitric oxide with the INOpulse® DS drug-delivery system as a drug-device combination product in pulmonary arterial hypertension (PAH) and chronic obstructive pulmonary disease (COPD). Ikaria's late-stage pipeline is also comprised of LUCASSIN® (terlipressin), a potential treatment for Hepatorenal Syndrome Type 1; as well as Bioabsorbable Cardiac Matrix (BCM), a potential treatment for preventing cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction. Ikaria is headquartered in Hampton, NJ, with a research facility in Madison, WI, and manufacturing facilities in Port Allen, LA and Madison, WI.  Please visit www.ikaria.com.Company Contact:Media Contact:Samina Bari

Claire SojdaIkaria, Inc.

Tiberend Strategic Advisors, Inc.(908) 238-6372  

(212) 827-0020samina.bari@ikaria.com

csojda@tiberend.com 

  

 


'/>"/>
SOURCE Ikaria, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ikaria® to Present at 14th Annual BIO CEO & Investor Conference
2. Ikaria® to Present at 2011 BIO Investor Forum
3. Ikaria® To Present at 2011 BIO Business Forum and International Convention
4. GeneLink Biosciences Completes Sale of GeneWize Life Sciences
5. CitiusTech Completes Another Milestone Year: Revenues Grow by 59% in 2011
6. Auxogyn Completes $20 Million In Series A Funding
7. goBalto Completes a Successful FDA 21 CFR Part 11 Compliance Audit
8. MiMedx Group Completes $5,000,000 Private Placement
9. PDL BioPharma Completes Regular Quarterly Dividend Payment
10. CeNeRx BioPharma Completes $4.85 Million Financing
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... , Jan. 16, 2017   Valentin A. ... Tracey, MD , president and CEO of The ... completed an analysis of how the nervous system regulates ... and develop bioelectronic medicine devices to treat ... Nature Neuroscience . The paper examines ...
(Date:1/13/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The biosimilars market is expected to reach USD ... a CAGR of 26.3%. The global biosimilars market ... Factors such as rising incidence of various diseases, increasing demand for ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... Vertebral Technologies, Inc., announces the successful outcome of the first lumbar fusion ... VTI (Vertebral Technologies, Inc.) has partnered with Mexico-based medical product company BioMedical ...
(Date:1/12/2017)... 12, 2017 The Energy and ... facility for producing mycorrhizae. The Centre for Mycorrhizal Research ... of mycorrhizae and developed a technology that eventually produces ... ... The TERI facility has a production capacity ...
Breaking Biology Technology:
(Date:1/4/2017)... , Jan. 4, 2017  CES 2017 – ... sensor technology, today announced the launch of two ... systems, the highly-accurate biometric sensor modules that incorporate ... technology, experience and expertise. The two new designs ... specifically for hearables, and Benchmark BW2.0, a 2-LED ...
(Date:12/20/2016)... , Dec. 20, 2016 The rising ... rental and leasing is stoking significant interest in ... frequency technology, Bluetooth low energy (BLE), biometrics and ... the next wave of wireless technologies in the ... system to advanced access systems opens the market ...
(Date:12/16/2016)... , Dec 16, 2016 Research and ... System Market - Global Forecast to 2021" report to their ... The ... to grow at a CAGR of 14.06% from 2016 to 2021. ... and is projected to reach 854.8 Million by 2021. The growth ...
Breaking Biology News(10 mins):